Pharma executives don’t lose in Eurasia because they “missed a filing.” They lose because they misunderstood the game.
Eurasia looks familiar on the surface—patents, exclusivity, regulatory approvals, enforcement. But the reality is messier: fragmented…

Pharmaceutical patent strategy is often treated like a binary choice: fight for every right—or give up and move on.
But the real winners don’t “decide” in the abstract. They run a decision matrix.
In a recent DrugPatentWatch piece, the core idea is sim…

The clock is ticking—and commercial market access vendors know it.
In pharma, timing isn’t a metaphor. It’s a margin. It’s a formulary decision. It’s a payer contract. And increasingly, it’s a race against the “drug patent clock” that can flip a prod…

Before You Launch: The Freedom-to-Operate (FTO) Checklist That Can Save Your Company From a “No” Letter
Launching a drug is a high-wire act. You’ve got clinical data, manufacturing timelines, payer conversations, and investor expectations—all moving at…

Drug patents in Asia-Pacific: the protection you think you have vs. the protection you actually get
If you’re building a pipeline—or underwriting one—you’ve probably heard the same comforting phrase: “Patent protection lasts X years.”
But in Asia-Pac…

Sell the line before the patent breaks.
In generic pharma, timing isn’t a marketing slogan—it’s a competitive advantage. The companies that win the next wave of demand aren’t always the ones with the best science or the lowest cost. Often, they’re th…